NES
CATX icon

New England Securities’s Perspective Therapeutics CATX Stock Holding History

New England Securities’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-2,000
Closed -$44K – 1736
2014
Q1 		$44K Sell
2,000
-1,000
-33% -$10.2K 0.02% 594
2013
Q4 		$15K Buy
+3,000
New +$15.8K 0.01% 912

Other funds holding CATX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $302M AUM 117.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

New England Securities's CATX Position: Q2 2014 in Review

New England Securities sold out of Perspective Therapeutics (CATX) in Q2 2014, closing a stake of 2,000 shares — an estimated $44K sold.

New England Securities first reported a position in CATX in Q4 2013 and held it in 2 quarters. The position peaked at $44K in Q1 2014. 26 funds tracked by Wall St. Rank hold CATX as of Q2 2014.

  • New England Securities reported no remaining Perspective Therapeutics position as of Q2 2014 after selling out during the quarter.
  • New England Securities sold 2,000 Perspective Therapeutics shares in Q2 2014, an estimated $44K.
  • New England Securities first reported a position in Perspective Therapeutics in Q4 2013 and held it in 2 quarters.
  • New England Securities's Perspective Therapeutics position peaked at $44K in Q1 2014.
  • 26 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2014.

Based on New England Securities's 13F filing for Q2 2014, filed 4 Aug 2014.